RBC Capital raised the firm’s price target on Emerson (EMR) to $169 from $161 and keeps an Outperform rating on the shares after its Q2 results. Proactive cost management allowed management to raise the low-end of FY26 EPS guidance while assuming 1 percentage point of continued Middle East disruption, lowering organic sales guidance from 4% to 3%, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EMR:
- Christopher Snyder Initiates Sell on Emerson Amid Cut Growth Outlook and Questionable Second‑Half Reacceleration
- Emerson Electric Earnings Call Highlights Profitable Resilience
- Emerson Electric Posts Strong Q2 Results, Reaffirms 2026 Outlook
- Emerson reports Q2 adjusted EPS $1.54, consensus $1.53
- Emerson sees Q3 adjusted EPS $1.65-$1.70, consensus $1.68
